Life sciences briefing: Monday, Feb. 4, 2008
TODAY’S HEADLINES:
PEAK Surgical takes in $21M for electrosurgical tools (release)
CellGate acquired by Australian cancer biotech ProGen for $2.5M (release)
Traversa raises $2M for RNAi-delivery technologies (release)
RemitDATA, Web-based healthcare-service co., takes in $5.5M (bizjournals.com)
Spinal-implant maker Archus Orthopedics gets $10M venture loan (release)
Promedior pulls down another $5.5M for fibrotic disease (release)
Acrongenomics takes 11 percent stake in Molecular Vision (release)
Hepatitis drug-developer Biolex withdraws IPO (IPO Home)
Employee drug screener eScreen gets Carlyle investment (release)
NovaMin raises $2.5M for dental-care products (VentureWire)
Cardious… Continue Reading
Life sciences briefing: Monday, Nov. 19, 2007
Featured companies: Alere Medical, AorTx, BioMedical Innovations, Cavidi, Centice, Integrated BioPharma, Oxitech, Nastech
UPDATED: Expanded items on Centice, AorTx and Alere Medical.
Centice raises $11M for drug-safety technology — Centice, a Morrisville, N.C., developer of computer-sensor systems, raised $11 million in a second funding round. Investors included S-Group Direct Investments, the Aurora Funds, Novak Biddle Venture Partners, Innovation Ventures and several individuals.
The funding will further Centice’s work on the Pass Rx system, a sensor designed to ensure the authenticity… Continue Reading
Life sciences briefing: Friday, Oct. 19, 2007
Featured companies: DirectFlow, Direvo, Indigo Biosystems, MacroGenics
Direct Flow raises $27M for heart-valve implants — Santa Rosa, Calif.-based Direct Flow Medical, a startup developing heart implants, raised $27 million in a second funding round. Investors included Johnson & Johnson Development, Foundation Medical Partners, VantagePoint Venture Partners, ePlanet, EDF Ventures, New Leaf Venture Partners and Spray Venture Partners.
Direct Flow makes minimally invasive aortic-valve replacements for the heart. This particular field happens to be booming — we’ve previously covered… Continue Reading
Life sciences briefing: Monday, Sept. 24, 2007
Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital
[NOTE: This item is a catchup daily briefing originally posted on 9/27/07. I've edited the item's timestamp to preserve the chronological order of the briefings. --D.P.H.]
Adnexus Thera cancels IPO, sells itself to Bristol-Myers for $430M — Waltham, Mass.-based Adnexus Therapeutics, a biotech pursuing drugs against cancer and other diseases, said it would cancel plans for its IPO and instead sell… Continue Reading